HIGH POTENCY APIS effects if a person is exposed at or below that level every day over a lifetime. 2
The ADE provides the compoundspecific toxicological anchor from which an OEL can be derived. This determines what engineering and procedural controls must be in place before a compound can be handled in a manufacturing environment.
The practical tool for translating OELs into manufacturing practice is the OEB framework, originally described by Naumann et al. as a performance-based approach to categorising APIs by potency and assigning appropriate containment methodologies to each category. 3 These run from Band 1( compounds handled safely in open systems) through Band 5( substances active at nanogram levels and requiring full engineering isolation at every handling step).
The industry is now seeing a meaningful increase in the proportion of clinical-stage compounds classified at Band 4 or 5 from the earliest development phases. For drug developers, this has practical implications: a smaller pool of facilities capable of handling these compounds, increased competition for capacity and a greater need to align development decisions with the realities of contained manufacturing from the outset. 4
RS 40 building & OEB5 workshop
Containment engineering
The purpose of containment engineering in HPAPI manufacture is precise: to prevent a compound that is biologically active at trace concentrations from reaching any unintended target. In practice, containment also determines reliability.
Failures translate directly into batch loss, regulatory risk or delays to clinical and commercial timelines. Achieving this consistently, across an entire manufacturing campaign and over the full lifetime of a production facility, requires that the engineering controls function as a coherent system rather than a collection of individual measures.
The primary layer of that system for Band 5 compounds is physical isolation of the handling environment. Maintained negative pressure differentials, dedicated and independently managed exhaust ventilation and barrier technology that allows operators to carry out all process steps without breaking containment are the engineering prerequisites.
These controls must extend without interruption across every handling step, including the transitions, which are statistically the points of greatest risk in any contained process. A charging operation conducted inside an isolator provides no protection if the subsequent transfer to the reactor is performed in open air.
Verifying that these controls are working to their specified standard requires a monitoring programme designed to detect failures at the lowest possible concentration, before they escalate into reportable deviations or impact product quality. This means analytical detection capability matched to the OEL of each compound, applied both to the working environment and to surfaces, airlocks and clean areas adjacent to the production zone.
Cleaning validation between campaigns requires the same analytical sensitivity and demonstrating the absence of crosscontamination between products is increasingly a focus of regulatory inspection at multi-product HPAPI facilities. 2 However, reproducibility and successful scale-up depend not only on containment engineering and analytical capability but also on the robustness of operational procedures and workforce training.
Standardised processes, operator qualification and ongoing training programmes are essential to ensure controls are applied consistently across campaigns, sites and scales of production. For developers, the effectiveness of containment engineering is therefore measured not only by exposure limits achieved but also by the absence of disruption- the ability to execute campaigns predictably, reproducibly and at scale, without unexpected intervention.
Development bottlenecks
The chemistry and process development phase is where HPAPI projects most often slip on regulatory timelines and where the choice of manufacturing partner has its earliest and biggest impact. Three failure modes show up consistently across programmes.
The first is the discovery, during technology transfer, that the synthetic route developed at laboratory scale is incompatible with contained manufacture, often after
JUL / AUG 2026 SPECCHEMONLINE. COM
15